SGLT2 inhibitors and kidney outcomes across the spectrum of kidney disease: a systematic review and meta-analysis

SGLT2 inhibitors have shown to reduce clinically meaningful kidney outcomes in individuals with chronic kidney disease at high risk for adverse outcomes. The effect of these agents in preventing clinically meaningful kidney outcomes in populations at lower risk remain uncertain. We aim to evaluate the effect of SGLT2 inhibitors on kidney outcomes across the Kidney Disease: Improving Global Outcomes (KDIGO) classification and urinary albumin-to-creatinine ratio (UACR) levels.